Welcome to our dedicated page for Precision Biosciences SEC filings (Ticker: DTIL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Precision BioSciences, Inc. filings document regulatory disclosures for a clinical-stage gene editing company built around the ARCUS platform and in vivo therapeutic candidates. Recent Forms 8-K furnish operating results, financial-condition updates, business presentations, and Regulation FD materials covering PBGENE-HBV in chronic hepatitis B and PBGENE-DMD in Duchenne muscular dystrophy, including IND-related and clinical-development disclosures.
The company’s proxy materials address board and stockholder meeting matters, executive compensation, equity plans, and governance proposals. Other filing categories cover material agreements, shareholder voting matters, capital-structure disclosures, inducement awards, and forward-looking risk language tied to clinical development, financing capacity, regulatory review, and public-company reporting.
Brown Melinda reported acquisition or exercise transactions in this Form 4 filing.
PRECISION BIOSCIENCES INC director Melinda Brown received a grant of 20,979 restricted stock units (RSUs) tied to common stock. Each RSU represents a right to receive one share of common stock. The RSUs vest on the earlier of June 3, 2027, or the day before the company’s next annual stockholder meeting following the grant date, assuming she continues serving the company through that vesting date. After this grant, she holds 20,979 RSUs directly.
Frankel Stanley reported acquisition or exercise transactions in this Form 4 filing.
PRECISION BIOSCIENCES INC director Stanley Frankel received a grant of 20,979 restricted stock units. Each RSU represents a contingent right to one share of common stock. The RSUs vest on the earlier of June 3, 2027 or the day before the next annual stockholder meeting, subject to his continued service.
Germano Geno J reported acquisition or exercise transactions in this Form 4 filing.
PRECISION BIOSCIENCES INC director Geno J. Germano received a grant of 20,979 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the company’s common stock. The RSUs vest on the earlier of June 3, 2027 or the day immediately before the next annual stockholders’ meeting following the grant date, subject to his continued service with the company.
Pire Shari Lisa reported acquisition or exercise transactions in this Form 4 filing.
PRECISION BIOSCIENCES INC director Shari Lisa Pire received a new equity grant. She was awarded 20,979 restricted stock units (RSUs), each representing a right to receive one share of the company’s common stock if vesting conditions are met.
The RSUs vest on the earlier of June 3, 2027 or the day immediately before the company’s next annual stockholder meeting following the grant date, provided she continues serving the company through that vesting date. After this grant, she holds 20,979 RSUs directly.
Buehler Kevin reported acquisition or exercise transactions in this Form 4 filing.
PRECISION BIOSCIENCES INC director Kevin Buehler received a grant of 20,979 Restricted Stock Units (RSUs), each representing a contingent right to one share of common stock. These RSUs vest on the earlier of June 3, 2027, or the day immediately before the company’s next annual stockholder meeting, subject to his continued service. Following this compensation-related award, Buehler holds 20,979 RSUs directly.
PRECISION BIOSCIENCES INC Chief Research Officer J. Jefferson Smith received a grant of 57,389 Restricted Stock Units. Each unit represents a contingent right to receive one share of common stock, so this award could convert into 57,389 shares if fully vested.
The RSU award vests in three substantially equal annual installments beginning on February 19, 2027, conditioned on Smith’s continued service with the company through each vesting date. Following this grant, Smith’s reported derivative holdings from this award total 57,389 RSUs, reflecting a compensation-related equity grant rather than an open-market purchase or sale.
Scimeca Dario reported acquisition or exercise transactions in this Form 4 filing.
PRECISION BIOSCIENCES INC reported that its General Counsel and Secretary, Dario Scimeca, received a grant of 107,604 restricted stock units. Each unit represents a contingent right to receive one share of the company’s common stock at no purchase price.
The award vests in three substantially equal annual installments beginning on February 18, 2027, conditioned on his continued service with the company through each vesting date. Following this grant, he holds 107,604 restricted stock units directly.
PRECISION BIOSCIENCES INC reported that Chief Financial Officer Kelly John Alexander received a grant of 193,688 Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of common stock at no exercise price. The award vests in three substantially equal annual installments beginning on February 19, 2027, conditioned on his continued service with the company through each vesting date. Following this grant, he is reported as holding 193,688 RSUs directly.
Amoroso Michael reported acquisition or exercise transactions in this Form 4 filing.
PRECISION BIOSCIENCES INC President and CEO Michael Amoroso reported a compensation-related equity grant. He received 573,888 Restricted Stock Units, each representing a contingent right to receive one share of the company’s common stock. The award vests in three substantially equal annual installments beginning on February 18, 2027, conditioned on his continued service with the company. Following this grant, his reported holding of these RSUs is 573,888 units.
Precision BioSciences reported new Phase 1 ELIMINATE-B data for its gene-editing therapy PBGENE-HBV in chronic hepatitis B. Liver biopsies showed direct elimination of cccDNA with a 1-log (10-fold) reduction in cccDNA-derived transcripts after dosing, and further edits in the small fraction remaining inactivated viral polymerase to stop replication.
Blood pgRNA, a marker that comes from cccDNA, was completely lost in 100% of treated patients with detectable pgRNA at baseline, and all evaluated patients showed substantial HBsAg declines, suggesting broad antiviral activity. Across 38 doses in 16 patients, no dose-limiting toxicities occurred; common effects were short-lived infusion reactions and reversible liver enzyme elevations. A mitigation protocol for hypotension and liver labs has been implemented, with no new Grade 3 events reported since.